Literature DB >> 17681352

DNA topoisomerase II, genotoxicity, and cancer.

A Kathleen McClendon1, Neil Osheroff.   

Abstract

Type II topoisomerases are ubiquitous enzymes that play essential roles in a number of fundamental DNA processes. They regulate DNA under- and overwinding, and resolve knots and tangles in the genetic material by passing an intact double helix through a transient double-stranded break that they generate in a separate segment of DNA. Because type II topoisomerases generate DNA strand breaks as a requisite intermediate in their catalytic cycle, they have the potential to fragment the genome every time they function. Thus, while these enzymes are essential to the survival of proliferating cells, they also have significant genotoxic effects. This latter aspect of type II topoisomerase has been exploited for the development of several classes of anticancer drugs that are widely employed for the clinical treatment of human malignancies. However, considerable evidence indicates that these enzymes also trigger specific leukemic chromosomal translocations. In light of the impact, both positive and negative, of type II topoisomerases on human cells, it is important to understand how these enzymes function and how their actions can destabilize the genome. This article discusses both aspects of human type II topoisomerases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17681352      PMCID: PMC2679583          DOI: 10.1016/j.mrfmmm.2007.06.009

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  183 in total

Review 1.  Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q.

Authors:  R DeVore; J Whitlock; J D Hainsworth; D H Johnson
Journal:  Ann Intern Med       Date:  1989-05-01       Impact factor: 25.391

Review 2.  DNA topoisomerases.

Authors:  J C Wang
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

3.  Function of DNA topoisomerases as replication swivels in Saccharomyces cerevisiae.

Authors:  R A Kim; J C Wang
Journal:  J Mol Biol       Date:  1989-07-20       Impact factor: 5.469

4.  Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide.

Authors:  N Osheroff
Journal:  Biochemistry       Date:  1989-07-25       Impact factor: 3.162

5.  Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22.

Authors:  M Tsai-Pflugfelder; L F Liu; A A Liu; K M Tewey; J Whang-Peng; T Knutsen; K Huebner; C M Croce; J C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

Review 6.  DNA topoisomerase II mutations and resistance to anti-tumor drugs.

Authors:  Y S Vassetzky; G C Alghisi; S M Gasser
Journal:  Bioessays       Date:  1995-09       Impact factor: 4.345

7.  Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae.

Authors:  S T Worland; J C Wang
Journal:  J Biol Chem       Date:  1989-03-15       Impact factor: 5.157

8.  DNA binding by epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of topoisomerase II inhibition.

Authors:  K C Chow; T L Macdonald; W E Ross
Journal:  Mol Pharmacol       Date:  1988-10       Impact factor: 4.436

9.  Human DNA topoisomerases II alpha and II beta can functionally substitute for yeast TOP2 in chromosome segregation and recombination.

Authors:  S Jensen; C S Redwood; J R Jenkins; A H Andersen; I D Hickson
Journal:  Mol Gen Genet       Date:  1996-08-27

10.  Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites.

Authors:  P L Broeker; H G Super; M J Thirman; H Pomykala; Y Yonebayashi; S Tanabe; N Zeleznik-Le; J D Rowley
Journal:  Blood       Date:  1996-03-01       Impact factor: 22.113

View more
  116 in total

1.  Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions.

Authors:  Adam C Ketron; William A Denny; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2012-02-10       Impact factor: 3.162

2.  Concentration-response studies of the chromosome-damaging effects of topoisomerase II inhibitors determined in vitro using human TK6 cells.

Authors:  P Gollapudi; V S Bhat; D A Eastmond
Journal:  Mutat Res       Date:  2019-05-15       Impact factor: 2.433

3.  Suppression of topoisomerase IIalpha expression and function in human cells decreases chromosomal radiosensitivity.

Authors:  Samantha Y A Terry; Andrew C Riches; Peter E Bryant
Journal:  Mutat Res       Date:  2009-02-04       Impact factor: 2.433

4.  DNA Topology and Topoisomerases: Teaching a "Knotty" Subject.

Authors:  Joseph E Deweese; Michael A Osheroff; Neil Osheroff
Journal:  Biochem Mol Biol Educ       Date:  2008       Impact factor: 1.160

5.  Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia.

Authors:  Ashley N Mays; Neil Osheroff; Yuanyuan Xiao; Joseph L Wiemels; Carolyn A Felix; Jo Ann W Byl; Kandeepan Saravanamuttu; Andrew Peniket; Robert Corser; Cherry Chang; Christine Hoyle; Anne N Parker; Syed K Hasan; Francesco Lo-Coco; Ellen Solomon; David Grimwade
Journal:  Blood       Date:  2009-11-02       Impact factor: 22.113

6.  Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage.

Authors:  Amanda C Gentry; Steven L Pitts; Michael J Jablonsky; Christian Bailly; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2011-03-28       Impact factor: 3.162

Review 7.  SUMO modification of DNA topoisomerase II: trying to get a CENse of it all.

Authors:  Ming-Ta Lee; Jeff Bachant
Journal:  DNA Repair (Amst)       Date:  2009-02-20

Review 8.  Molecular biology of therapy-related leukaemias.

Authors:  Melanie Joannides; David Grimwade
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

9.  Proteolytic degradation of topoisomerase II (Top2) enables the processing of Top2·DNA and Top2·RNA covalent complexes by tyrosyl-DNA-phosphodiesterase 2 (TDP2).

Authors:  Rui Gao; Matthew J Schellenberg; Shar-Yin N Huang; Monica Abdelmalak; Christophe Marchand; Karin C Nitiss; John L Nitiss; R Scott Williams; Yves Pommier
Journal:  J Biol Chem       Date:  2014-05-07       Impact factor: 5.157

10.  Bimodal recognition of DNA geometry by human topoisomerase II alpha: preferential relaxation of positively supercoiled DNA requires elements in the C-terminal domain.

Authors:  A Kathleen McClendon; Amanda C Gentry; Jennifer S Dickey; Marie Brinch; Simon Bendsen; Anni H Andersen; Neil Osheroff
Journal:  Biochemistry       Date:  2008-12-16       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.